pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR
ME Therapeutics
Marker Therapeutics
ME Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker MRKR. Primary therapeutic focus areas include Colorectal Cancer Screening, Screening for Colon Cancer, Platinum Sens
Vancouver, British Columbia, CA HQ
2018 Founded
4 Employees
Public company Type
MRKR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Vancouver, British Columbia, CA
- Founded
- 2018
- Employees
- 4
- Programs
- 13
- Drugs
- 10
- Patents
- 27
MT-601
Phase 1 · small molecule · Non-Hodgkin Lymphoma, Adult
MT-601 for Non-Hodgkin Lymphoma, Adult is a Phase 1 program (small_molecule) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MRKR-22-601-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Marker Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Non-Hodgkin Lymphoma, Adult
- Status
- active
- Trials
- 1